Akebia Therapeutics, Inc.
AKBA
$1.18
$0.032.61%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 53.54M | 57.62M | 58.77M | 62.47M | 57.34M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.54M | 57.62M | 58.77M | 62.47M | 57.34M |
| Cost of Revenue | 9.78M | 10.93M | 10.28M | 10.72M | 8.16M |
| Gross Profit | 43.76M | 46.69M | 48.49M | 51.76M | 49.17M |
| SG&A Expenses | 30.44M | 26.09M | 29.09M | 26.56M | 25.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.02M | 63.67M | 54.32M | 48.28M | 43.66M |
| Operating Income | -1.48M | -6.05M | 4.45M | 14.19M | 13.68M |
| Income Before Tax | -8.93M | -11.24M | 1.16M | 247.00K | 6.11M |
| Income Tax Expenses | 126.00K | 1.01M | 615.00K | -- | -- |
| Earnings from Continuing Operations | -9.05M | -12.24M | 540.00K | 247.00K | 6.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.05M | -12.24M | 540.00K | 247.00K | 6.11M |
| EBIT | -1.48M | -6.05M | 4.45M | 14.19M | 13.68M |
| EBITDA | -1.15M | -5.73M | 4.77M | 14.51M | 13.99M |
| EPS Basic | -0.03 | -0.05 | 0.00 | 0.00 | 0.03 |
| Normalized Basic EPS | -0.01 | -0.02 | 0.00 | 0.00 | 0.02 |
| EPS Diluted | -0.03 | -0.05 | 0.00 | 0.00 | 0.03 |
| Normalized Diluted EPS | -0.01 | -0.02 | 0.00 | 0.00 | 0.02 |
| Average Basic Shares Outstanding | 267.05M | 265.37M | 264.79M | 262.57M | 235.50M |
| Average Diluted Shares Outstanding | 267.05M | 265.37M | 274.37M | 271.10M | 241.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |